Attana plans to move production of consumables to AroCell

Attana can today announce that the company has begun a discussion about moving production of consumables, e.g., sensor chips, to the in vitro diagnostics company AroCell AB (Publ).

Attana plans to move production of consumables such as sensor chips and reagents to AroCell. The purpose of the move is to be able to handle increased volumes in order to improve margins. In addition, the move enables better use of both companies' resources and expertise.

Teodor Aastrup, CEO of Attana, comments:

“AroCell's experience and production capacity fit in well with producing Attana's consumables. This increases our flexibility as well as our production margins while freeing up internal resources.”

Anders Hultman, CEO of AroCell, comments:

“We look forward to being able to apply our expertise and resources in the production of Attana's consumables. It is also an important step in increasing our revenues and margins in our production unit.”

For more information, please contact:

Teodor Aastrup, CEO
teodor.aastrup@attana.com
+46 (0)8 674 57 00

The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.

About Attana

Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact sales@attana.com

Tags: